Compare Dollar General Corp. (DG) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Quest Diagnostics Inc — how do they compare? Dollar General Corp. trades at $127.06 (market cap $27.42B), while Quest Diagnostics Inc trades at $230.79 (market cap $25.48B). The key difference: Dollar General Corp. and Quest Diagnostics Inc are close in size by market cap, and Dollar General Corp. pays the higher dividend (1.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Quest Diagnostics Inc for 56 Days on average.
| DG | DGX | |
|---|---|---|
Market Cap | $27.42B | $25.48B |
Volume | 2,291,517 | 941,866 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $247.45 |
52-Week Low | $95.94 | $173.49 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $41.60B | $31.23B |
Dividend Yield | 1.9% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $126.16, up 3.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows solid fundamentals with a P/E of 16.14 and ROE of 19.69%, supported by positive cash flow trends and a growing revenue base. Recent news highlights strategic initiatives like tariff refunds, delivery expansion with Instacart, and the DG Media Network, enhancing its value-retail positioning.
The outlook for DG is positive, driven by earnings momentum and analyst consensus pointing to a $137.27 price target. Key opportunities include margin expansion from cost initiatives and digital growth, while risks involve competitive pressures and consumer spending sensitivity. The stock presents a compelling case for value investors seeking steady growth in the discount retail sector.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
